Acer Therapeutics Inc. (ACER) Analysts See $-0.55 EPS

July 14, 2018 - By Robert Reynolds

Analysts expect Acer Therapeutics Inc. (NASDAQ:ACER) to report $-0.55 EPS on August, 13.They anticipate $0.38 EPS change or 40.86 % from last quarter’s $-0.93 EPS. After having $-0.53 EPS previously, Acer Therapeutics Inc.’s analysts see 3.77 % EPS growth. The stock decreased 5.51% or $1.3 during the last trading session, reaching $22.3. About 18,011 shares traded or 26.83% up from the average. Acer Therapeutics Inc. (NASDAQ:ACER) has risen 171.45% since July 14, 2017 and is uptrending. It has outperformed by 158.88% the S&P500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $167.19 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

More recent Acer Therapeutics Inc. (NASDAQ:ACER) news were published by: Benzinga.com which released: “35 Stocks Moving In Friday’s Mid-Day Session” on June 29, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” on June 29, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Titan’s Parkinson’s Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32 …” with publication date: July 03, 2018 was also an interesting one.

Acer Therapeutics Inc. (NASDAQ:ACER) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.